MYDAYIS
Peakdextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate
NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYDAYIS is an extended-release oral capsule combining four amphetamine salts (dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate). It is a central nervous system stimulant indicated for attention-deficit/hyperactivity disorder (ADHD). The extended-release formulation provides once-daily dosing designed to maintain therapeutic levels throughout the day.
$3MPart D
Peak3.3 years to LOEProduct is in peak lifecycle phase with modest Medicare Part D penetration; commercial teams are focused on maintaining market position against high competitive pressure (8/10 intensity).
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on MYDAYIS at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.